Ajanta Pharma Intrinsic Value
Ajanta Pharma intrinsic value. Ajanta Pharma (AJANTPHARM) median intrinsic value is ₹2734.16 from 10 valuation models (range ₹981–₹6541), vs current price ₹3270.30 — -16.4% downside (Trading Above Median Value), margin of safety -19.6%. For current market price and key ratios, visit Ajanta Pharma stock price NSE.
AJANTPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Ajanta Pharma intrinsic value across 10 models vs current price ₹3270.30 — upside/downside and value range per method. Analyse AJANTPHARM shareholding pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2734.16 | ₹2187.33 - ₹3280.99 | -16.4% | EPS: ₹124.28, Sector P/E: 22x |
| Book Value Method | asset | ₹3621.60 | ₹3259.44 - ₹3983.76 | +10.7% | Book Value/Share: ₹1810.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹5862.40 | ₹5276.16 - ₹6448.64 | +79.3% | Revenue/Share: ₹2931.20, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹6540.60 | ₹5886.54 - ₹7194.66 | +100.0% | EBITDA: ₹2340.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1964.45 | ₹1571.56 - ₹2357.34 | -39.9% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹981.09 | ₹882.98 - ₹1079.20 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1920.13 | ₹1728.12 - ₹2112.14 | -41.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹6540.60 | ₹5886.54 - ₹7194.66 | +100.0% | ROE: 34.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹2250.23 | ₹2025.21 - ₹2475.25 | -31.2% | EPS: ₹124.28, BVPS: ₹1810.80 |
| Dividend Yield Method | dividend | ₹1120.00 | ₹1008.00 - ₹1232.00 | -65.8% | DPS: ₹28.00, Target Yield: 2.5% |
AJANTPHARM Intrinsic Value vs Market Price — All Valuation Models
Ajanta Pharma fair value range ₹981–₹6541 vs current market price ₹3270.30 across 10 valuation models. Browse Ajanta Pharma annual reports for revenue, profit, balance sheet and cash flow data.
AJANTPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Ajanta Pharma median intrinsic value ₹2734.16, current price ₹3270.30 — Trading Above Median Value by 16.4%, margin of safety -19.6%.
What is the intrinsic value of AJANTPHARM?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Ajanta Pharma (AJANTPHARM) is ₹2734.16 (median value). With the current market price of ₹3270.30, this represents a -16.4% variance from our estimated fair value.
The valuation range spans from ₹981.09 to ₹6540.60, indicating ₹981.09 - ₹6540.60.
Is AJANTPHARM undervalued or overvalued?
Based on our multi-method analysis, Ajanta Pharma (AJANTPHARM) appears to be trading above median value by approximately 16.4%.
AJANTPHARM Financial Health — Key Ratios vs Industry Benchmarks
Ajanta Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 34.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.19x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
AJANTPHARM Cash Flow Quality — Operating & Free Cash Flow
Ajanta Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹529 Cr | ₹315 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹1,157 Cr | ₹969 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹785 Cr | ₹785 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹792 Cr | ₹512 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹562 Cr | ₹525 Cr | Positive Free Cash Flow | 8/10 |